Cabergoline as a preventive migraine treatment: A randomized clinical pilot trial.

ABSTRACT:

Background

Beneficial effects of dopamine agonist treatment on migraine have been reported but remain to be properly tested. The aim of this study was to examine the effect of cabergoline as preventive treatment for migraine.

Methods

In a double-blind, placebo-controlled pilot study, 36 adults with ≥  6 monthly migraine days were enrolled at Aarhus University Hospital. Following a 28-days baseline period, participants were randomized to receive cabergoline 0.5 mg or placebo once weekly for 12 weeks as add-on treatment. An electronic headache diary was completed daily, and headache questionnaires and blood tests were collected at baseline and following the treatment period. Primary outcome was change in monthly migraine days. The trial was registered with ClinicalTrials.gov (

SUBMITTER: Hjelholt AJ 

PROVIDER: S-EPMC11960899 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature